Stem Cell Transplantation

Recombinant erythropoietin therapy controls post-transplant anemia if timed right

Published in Blood Weekly, August 15th, 2002

by Michael Greer, senior medical writer - If initiated at the right time, recombinant human erythropoietin (rhEpo) therapy can resolve anemia in stem cell graft recipients, researchers say.

"Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with prolonged anemia caused by defective erythropoietin (Epo) production," explained Dr. Frederic Baron and colleagues working at the University of Liege in Liege, Belgium.

Although rhEpo treatment provided only limited benefit immediately after HSCT, the recombinant growth factor was highly effective when given at least 1 month after transplantation, Baron and coauthors found.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry